USPTO serial 86606877
SATIVOL
Reviewed by CopyMark Law Group
Status 601
- Filing date
- Status date
- Registration date
- —
- Examiner
- LOOK, JEFFREY J
- Law office
- TMEG LAW OFFICE 108 - EXAMINING ATTORNEY ASSIGNED
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SATIVOL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Patricia L. Werner
PATRICIA L. WERNER KELLEY DRYE & WARREN LLP101 PARK AVENEW YORK, NY 10178-0002UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 031 | cannabidiol (CBD) derived from industrial hemp for use in the manufacture of pharmaceuticals; soluble films for use in the manufacture of delivery agents for pharmaceuticals and vitamins; consumer products, namely, body care, skin care, hair care, cosmetics, and personal care products based on CBD derived from industrial hemp, namely, creams, oils, emollients, ointments, rubs, lotions, salves, shampoos, conditioners, hair treatments, scrubs, tonners, masks, drops, oils body wash, butters, exfoliants, moisturizers, and gels; pharmaceuticals, pharmaceutical preparations, and nutraceuticals for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; Dietary and nutritional supplements containing cannabidiol (CBD); pharmaceuticals, pharmaceutical preparations, and nutraceuticals containing CBD derived from industrial hemp for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; prescription synthetic narcotics for medical use; nutritional and dietary supplements; food supplements; medicines containing CBD derived from industrial hemp for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; magnetically encoded cards, namely, membership and identification cards; magnetically encoded cards for use in connection with customer loyalty, rewards, bonus points, and discount programs; magnetically encoded identification cards for use in connection with customer loyalty, rewards, bonus points, and discount programs; consumer products, namely, edible oils; consumer products, namely, non-alcoholic beverages, namely, soft drinks, fruit drinks, vegetable drinks, and juices; consumer products, namely, smokeless vaporizer pipes and pens; online retail store wholesale services featuring CBD based pharmaceutical and body care products derived from industrial hemp; mail order buying clubs in the field of pharmaceutical products; membership services, namely, the operation and maintenance of an association promoting the interests of retail and wholesale stores in the field of medical marihuana; membership services, namely, providing discounts and processing rebates for the goods and services of others in the medical marijuana industry; retail and wholesale store services featuring CBD based pharmaceutical products derived from industrial hemp; retail and wholesale store services featuring pharmaceuticals containing CBDs; promoting the goods and services of others by issuance of rewards cards related to the purchase of CBD based products; retail and wholesale store reward programs to promote the sale of pharmaceuticals containing CBDs; providing a customer loyalty program which promotes the goods and services of others by offering rewards, bonus points or discount offers; providing consumer information in the field of medical marijuana; providing a website featuring commercial information regarding medical marijuana dispensaries; providing a website featuring information regarding political and business information regarding the medical marijuana and cannabis industries; providing discounts and processing rebates for retail stores and wholesale stores in the medical marijuana field; assembly of pharmaceuticals for others; customized production of pharmaceuticals, pharmaceutical products, nutraceuticals and CBD based products derived from industrial hemp; extraction of CBD derived from industrial hemp; scientific research services in the area of CBD based products derived from industrial hemp; product development services for products containing CBD based products derived from industrial hemp; research and development of products containing CBDs for others for clinical studies; providing a website featuring information regarding scientific and medical research in the field of cannabis and medical marijuana; operation of a web site that provides online social networking; providing a website featuring legal information regarding marijuana, cannabis and CBDs based products derived from industrial hemp | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 28, 2017 | MAB1 | ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT | — |
| Jun 28, 2017 | ABN1 | ABANDONMENT - EXPRESS MAILED | — |
| Jun 27, 2017 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| May 31, 2017 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 31, 2017 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 31, 2017 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 11, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 11, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 9, 2017 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Feb 8, 2017 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jan 12, 2017 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 12, 2017 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 9, 2016 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Nov 9, 2016 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Nov 9, 2016 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Oct 18, 2016 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Apr 1, 2016 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 1, 2016 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 1, 2016 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Mar 4, 2016 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 4, 2016 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 4, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 4, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 26, 2016 | ALIE | ASSIGNED TO LIE | — |
| Feb 19, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 19, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 19, 2015 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 19, 2015 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 19, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 4, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| May 20, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| May 20, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| May 1, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |